ENTA vs. VALN, ARVN, MAZE, OPT, RGNX, CGEM, TYRA, AUTL, ETON, and ATAI
Should you be buying Enanta Pharmaceuticals stock or one of its competitors? The main competitors of Enanta Pharmaceuticals include Valneva (VALN), Arvinas (ARVN), Maze Therapeutics (MAZE), Opthea (OPT), REGENXBIO (RGNX), Cullinan Therapeutics (CGEM), Tyra Biosciences (TYRA), Autolus Therapeutics (AUTL), Eton Pharmaceuticals (ETON), and Atai Life Sciences (ATAI). These companies are all part of the "pharmaceutical products" industry.
Enanta Pharmaceuticals vs. Its Competitors
Valneva (NASDAQ:VALN) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, community ranking, valuation, earnings and risk.
Valneva currently has a consensus target price of $15.50, suggesting a potential upside of 152.03%. Enanta Pharmaceuticals has a consensus target price of $18.00, suggesting a potential upside of 142.91%. Given Valneva's stronger consensus rating and higher possible upside, equities research analysts plainly believe Valneva is more favorable than Enanta Pharmaceuticals.
In the previous week, Valneva had 2 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 7 mentions for Valneva and 5 mentions for Enanta Pharmaceuticals. Enanta Pharmaceuticals' average media sentiment score of 1.01 beat Valneva's score of 0.41 indicating that Enanta Pharmaceuticals is being referred to more favorably in the news media.
11.4% of Valneva shares are held by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are held by institutional investors. 14.9% of Valneva shares are held by insiders. Comparatively, 13.9% of Enanta Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Enanta Pharmaceuticals received 279 more outperform votes than Valneva when rated by MarketBeat users. However, 66.67% of users gave Valneva an outperform vote while only 57.02% of users gave Enanta Pharmaceuticals an outperform vote.
Valneva has higher revenue and earnings than Enanta Pharmaceuticals. Valneva is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Valneva has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500. Comparatively, Enanta Pharmaceuticals has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500.
Valneva has a net margin of -4.35% compared to Enanta Pharmaceuticals' net margin of -157.57%. Valneva's return on equity of -3.93% beat Enanta Pharmaceuticals' return on equity.
Summary
Valneva beats Enanta Pharmaceuticals on 13 of the 19 factors compared between the two stocks.
Get Enanta Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ENTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Enanta Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:ENTA) was last updated on 6/12/2025 by MarketBeat.com Staff
Buy ENTA Stock Free ENTA Stock Alerts